{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:18:21Z","timestamp":1793665101582,"version":"4.5.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapse after anti-CD19 chimeric antigen receptor (CD19-CAR) occurs in a substantial proportion of patients with lymphoid malignancies. We assessed the potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAbs) with CD19-CAR T cells with the aim of enhancing immunotherapeutic efficacy. Addition of CD20-BsAbs to cocultures of CD19-CARs and primary samples of B-cell malignancies, comprising malignant B cells and endogenous T cells, significantly improved killing of malignant cells and enhanced the expansion of both endogenous T cells and CD19-CAR T cells. In an immunocompetent mouse model of chronic lymphocytic leukemia, relapse after initial treatment response frequently occurred after CD19-CAR T-cell monotherapy. Additional treatment with CD20-BsAbs significantly enhanced the treatment response and led to improved eradication of malignant cells. Higher efficacy was accompanied by improved T-cell expansion with CD20-BsAb administration and led to longer survival with 80% of the mice being cured with no detectable malignant cell population within 8 weeks of therapy initiation. Collectively, our in\u00a0vitro and in\u00a0vivo data demonstrate enhanced therapeutic efficacy of CD19-CAR T cells when combined with CD20-BsAbs in B-cell malignancies. Activation and proliferation of both infused CAR T cells and endogenous T cells may contribute to improved disease control.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022682","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T18:58:34Z","timestamp":1716922714000},"page":"784-789","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in\u00a0vitro and CLL in\u00a0vivo models"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-2159","authenticated-orcid":false,"given":"Berit J.","family":"Brinkmann","sequence":"first","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"2Molecular Medicine Partnership Unit, Heidelberg, Germany"},{"name":"3Genome Biology, European Molecular Biology Laboratory, Heidelberg, Germany"},{"name":"4Clinical Cooperation Unit Molecular Hematology\/Oncology, German Cancer Research Center, Heidelberg, Germany"},{"name":"5Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5452-9417","authenticated-orcid":false,"given":"Alessia","family":"Floerchinger","sequence":"additional","affiliation":[{"name":"5Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany"},{"name":"6Molecular Genetics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2693-8086","authenticated-orcid":false,"given":"Christina","family":"Schniederjohann","sequence":"additional","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"2Molecular Medicine Partnership Unit, Heidelberg, Germany"},{"name":"5Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany"},{"name":"7Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"8Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Roider","sequence":"additional","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"2Molecular Medicine Partnership Unit, Heidelberg, Germany"},{"name":"3Genome Biology, European Molecular Biology Laboratory, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-1220","authenticated-orcid":false,"given":"Mariana","family":"Coelho","sequence":"additional","affiliation":[{"name":"5Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany"},{"name":"6Molecular Genetics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Mack","sequence":"additional","affiliation":[{"name":"6Molecular Genetics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-3109","authenticated-orcid":false,"given":"Peter-Martin","family":"Bruch","sequence":"additional","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"2Molecular Medicine Partnership Unit, Heidelberg, Germany"},{"name":"7Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"8Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Liebers","sequence":"additional","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"2Molecular Medicine Partnership Unit, Heidelberg, Germany"},{"name":"7Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"8Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"9Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"D\u00f6tsch","sequence":"additional","affiliation":[{"name":"10Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-093X","authenticated-orcid":false,"given":"Dirk H.","family":"Busch","sequence":"additional","affiliation":[{"name":"10Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany"},{"name":"11German Center for Infection Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"12German Cancer Consortium and German Cancer Research Center\/National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Neumann","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp M.","family":"Roessner","sequence":"additional","affiliation":[{"name":"6Molecular Genetics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5155-663X","authenticated-orcid":false,"given":"Martina","family":"Seiffert","sequence":"additional","affiliation":[{"name":"6Molecular Genetics, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[{"name":"1Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany"},{"name":"2Molecular Medicine Partnership Unit, Heidelberg, Germany"},{"name":"3Genome Biology, European Molecular Biology Laboratory, Heidelberg, Germany"},{"name":"7Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"8Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2024081515210295800_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024081515210295800_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10402","key":"2024081515210295800_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase\u00a01-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"13","key":"2024081515210295800_bib4","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024081515210295800_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024081515210295800_bib6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"2024081515210295800_bib7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024081515210295800_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"2024081515210295800_bib9","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discov"},{"issue":"15","key":"2024081515210295800_bib10","first-page":"1896","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"141","author":"Tong","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2024081515210295800_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T\u00a0cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2024081515210295800_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2024081515210295800_bib13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"2024081515210295800_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"issue":"suppl 16","key":"2024081515210295800_bib15","doi-asserted-by":"crossref","first-page":"e20049","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049","article-title":"Sequencing bispecific antibodies and CAR\u00a0T\u00a0cell therapy in multiple myeloma with\u00a0prior exposure to BCMA-targeted therapies","volume":"41","author":"Patel","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024081515210295800_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024081515210295800_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","article-title":"Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial","volume":"16","author":"Schubert","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"2024081515210295800_bib18","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024081515210295800_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in\u00a0vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2024081515210295800_bib20","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"23","key":"2024081515210295800_bib21","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1182\/bloodadvances.2021005400","article-title":"An autologous culture model of nodal B-cell lymphoma identifies ex\u00a0vivo determinants of response to bispecific antibodies","volume":"5","author":"Roider","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2024081515210295800_bib22","doi-asserted-by":"crossref","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within\u00a0the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"2024081515210295800_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen-loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"303","key":"2024081515210295800_bib24","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022682\/2237734\/blood_bld-2023-022682-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022682\/2237734\/blood_bld-2023-022682-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:21:22Z","timestamp":1723735282000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/7\/784\/516240\/CD20-bispecific-antibodies-improve-response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022682","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}